

BHRS FDA Guidelines for Indications and Dosage Ranges

Category	Generic Name	Route/ Formulation	Dosage	Frequency Range	FDA Indications	Comments
Antipsychotics	Aripiprazole	Oral tablet	2 to 30mg	QDay	Bipolar disorder, Irritability associated with autistic disorder, Major depressive disorder, Schizophrenia, Tourette disorder	
	Aripiprazole monohydrate (Ablify Maintena®)	IM Long acting Injectable (LAI)	300-400mg	Q monthly	Bipolar disorder, Schizophrenia	
	Aripiprazole Lauroxil (Aristada®)	IM / LAI	441-1064mg	Q4-8 weeks	Bipolar disorder, Schizophrenia	
	Aripiprazole monohydrate (Asimtufi®)	IM/LAI	720 mg/2.4 ML & 960 mg/3.2 ML	Q2 mos	Bipolar disorder, Schizophrenia	
	Asenapine (Saphris)	Sublingual tablet	5-10 mg/d	BID	Bipolar disorder, Schizophrenia	
		Transdermal patch (Secuado)	3.8-7.6 mg/d	Q 24hrs	Schizophrenia	
	Brexiprazole (Rexulti)	Oral tablet	0.25-4 mg/d	QDay	Agitation associated with dementia due to Alzheimer disease, Major depressive disorder, Schizophrenia	
	Cariprazine (Vraylar)	Oral capsule	0.5-6 mg/d	QDay	Bipolar disorder, Major depressive disorder, Schizophrenia	
	Chlorpromazine	Oral tablet	25-800 mg/d	BID to QID	Agitation/aggression associated with psychiatric disorders, Behavioral problems, Bipolar disorder, Hiccups, Hyperactivity, Nausea and vomiting, Presurgical apprehension, Schizophrenia, Tetanus	
	Clozapine	Oral tablet	6.25-900 mg/d	QDay to TID	Schizophrenia (treatment resistant), Suicidal behavior in schizophrenia or schizoaffective disorder	
	Dexmedetomidine (Igalmi)	Sublingual film	120 mcg & 180 mcg	Qday	Agitation associated with schizophrenia or bipolar I or II disorder	If agitation persists, up to 2 additional doses of 60 mcg or 90 mcg may be administered at least 2 hours apart. Maximum: 360 mcg/day.
	Fluphenazine	Oral tablet	1-20 mg/d	TID to QID	Psychotic disorders	Some patients may require up to 40 mg/day for symptom control (long-term safety of higher doses not established)
		Injectable - long acting	6.25-100mg	Q2-6 wks	Psychotic disorders	6.25 to 25 mg Q 2 weeks. Once at steady state, the effects of a single inj may last 4 to 6 weeks; titrate cautiously if doses >50 mg are needed, increase in 12.5 mg increments
	Haloperidol	Oral tablet	0.5-30 mg/d (100mg Max)	QDay	Behavioral disorders nonpsychotic, Hyperactivity, Schizophrenia, Tourette syndrome (management of tics)	Bipolar Disorder: Oral: Initial: 2 to 15 mg/day or 0.2 mg/kg/d (up to 15 mg/d), in 1 or 2 divided doses. May increase dose based on response and tolerability in increments of ≤5 mg as frequently as every 2 days up to 30 mg/d
	Haloperidol	Injectable - long acting	Initial: 10 to 20 times the daily oral dose Max: 450 mg	Q4 weeks	Schizophrenia	Oral overlap: Following the first ER decanoate dose, taper the oral dose by ~25% at weekly intervals during the second or third month of decanoate treatment. Adjust oral dose and rate of tapering based on clinical response and tolerability. Alternative regimen without overlap of PO haloperidol: Discontinue oral haloperidol immediately prior to the first inj when using this regimen. Initial: 20 times the daily oral dose. If the initial dose conversion requires >100 mg ER injection, administer the dose in 2 injections with a maximum of 100 mg for the first injection and the remainder given in 3 to 7 days. Maintenance dose: Reduce the ER decanoate dose during the second and third months (eg, by ~25% each month), then continue to adjust based on response and tolerability. Usual maintenance dose is 10 to 15 times the previous daily oral dose administered at 4-week intervals. Maximum dose: 450 mg every 4 weeks
	Iloperidone (Fanapt)	Oral tablet	1-24 mg/d	BID	Bipolar disorder, Schizophrenia	
	Loxapine	Oral capsule	20 mg to 250 mg/d	BID to QID	Schizophrenia, Agitation associated with schizophrenia or bipolar I disorder	
	Lurasidone (Latuda)	Oral tablet	20-160mg/d (120-160 MDD)	QDay	Bipolar disorder, Schizophrenia	
	Olanzapine	Oral and disintegrating tabs	2.5-20mg	QDay	Bipolar disorder, Major depressive disorder, Schizophrenia	xperts suggest some patients may require doses up to 50 mg/day for optimal response (CANMAT [Yatham 2018]; Citrome 2009; Stovall 2019).
	Olanzapine/Samidorphan l-malate (Lybalvi)	Oral tablet	10 mg-10mg, 15 mg-10 mg, 20 mg-10mg	QDay	Bipolar I disorder, Schizophrenia	may adjust dose based on response & tolerability in decrements/increments of 5 mg (based on the olanzapine component) to olanzapine 5 to 20 mg/samidorphan 10 mg once daily; maximum dose: olanzapine 20 mg/samidorphan 10 mg.
	Paliperidone	Oral tablet	3 to 12 mg	QDay	Schizophrenia, Schizoaffective disorder	
	Paliperidone palmitate (Invega Sustenna)	Injectable - long acting (Invega Sustenna)	39-234mg	Q month	Schizophrenia, Schizoaffective disorder	
	Paliperidone palmitate (Invega Trinza)	Injectable- long acting (Invega Trinza)	273 mg, 410 mg, 546 mg, 819 mg	Q 3 months	Schizophrenia	
	Paliperidone palmitate (Invega Hafyera)	Injectable- long acting (Invega Hafyera)	1092 mg, 1560 mg	Q 6 months	Schizophrenia	
	Perphenazine	Oral tablet	8-32 mg/d in divided doses	in divided doses	Nausea/vomiting, Schizophrenia	Doses as high as 64 mg/d may be appropriate in some situations
	Pimozide (Orap)	Oral tablet	0.5 mg to 10 mg/day (or 0.2 mg/kg/day whichever is less)	Qday	Tourette syndrome Off-Label: Adult Delusional infestation	Delusional infestation (off-label): If exceeding dose of 4 mg/day, CYP2D6 geno-/phenotyping should be performed.
	Quetiapine	Oral tablet	12.5 mg to 800 mg	QDay to BID	Bipolar disorder, Major depressive disorder, Schizophrenia	Some pts may require up to 1,200 mg/d for optimal response
		Oral tablet, Extended Release	300-800 mg	QDay	Bipolar disorder, Major depressive disorder, Schizophrenia	Some pts may require up to 1,200 mg/d for optimal response
	Risperidone	Oral and disintegrating tablet	0.25 to 8 mg/d	QDay to BID	Bipolar mania, Irritability associated with autistic disorder, Schizophrenia	Doses up to 16 mg/day have been evaluated in clinical trials and are approved according to manufacturer's labeling but are associated with increased adverse effects and generally are not recommended
		Injectable- long acting (Risperdal Consta)	25-50mg	Q 4 weeks	Schizophrenia, Bipolar I disorder	
		Injectable- long acting (Perseris)	90-120mg	Q month	Schizophrenia	
		Injectable- long acting (Rykindo)	25 mg to 50 mg	Q 2 weeks	Schizophrenia, Bipolar I disorder	
Subcutaneous LAI (Uzedyl®)		50mg/0.14mL to 250 mg/0.7 mL	Monthly or every-2-months	Schizophrenia	50 to 125 mg once monthly or 100 to 250 mg every 2 months. Available strengths: 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 200 mg, 250 mg	
Thiothixene	Oral capsule	6 to 60mg/d	BID to TID	Schizophrenia		
Thioridazine	Oral tablet	100 to 800mg/d	BID to QID	Schizophrenia		
Trifluoperazine	Oral tablet	4 mg to 20 mg/d (2 mg to 10 mg BID)	BID	Anxiety, Schizophrenia	Some patients may require up to 50 mg/day for symptom control (long-term safety of higher doses not established)	
Ziprasidone	Oral capsule	40 mg to 160 mg/d (20-80mg BID)	BID	Schizophrenia, Bipolar disorder	For some pts doses up to 240 mg/d may be necessary and tolerated	
Ziprasidone mesylate (Geodon)	Injectable IM	10 mg to 40 mg/day	Q 2 hours to Q 4 hours	Agitation/Aggression associated with psychiatric disorders, substance intoxications, or other organic causes		

Antidepressants

Amitriptyline	Oral tablet	25-300 mg/d	QHS or in divided doses	Major depressive disorder	
Amoxapine (Asendin®)	Oral tablet	25 mg to 400 mg/day	QDay to TID	Major depressive disorder	Maximum daily dose: 400 mg outpatient; 600 mg hospitalized patients
Bupropion	Oral tablet IR	200-450mg/d	BID to QID	Major depressive disorder	
Bupropion (Wellbutrin SR)	Oral tablet SR (12-hour ER)	100-450 mg/d	QDay to BID	Major depressive disorder	
Bupropion (Zyban)	Oral tablet SR (12-hour ER)	150-300 mg/d	QDay to BID	Smoking cessation	
Bupropion (Wellbutrin XL)	Oral tablet XR (24-hour ER)	150-450 mg/d	QDay	Major depressive disorder, prevention of seasonal affective disorder	
Bupropion/Dextromethorphan (Auvelity)	Oral tablet ER	Dextromethorphan 45 mg/bupropion 105 mg to dextromethorphan 90 mg/bupropion 210 mg/d	QD to BID	Major depressive disorder	
Citalopram (Celexa)	Oral tablet	10-40 mg/d	QDay	Major depressive disorder	
Clomipramine (Anafranil®)	Oral capsule	10 mg to 250 mg/d	QDay to TID	Obsessive-compulsive disorder	
Desipramine (Norpramin)	Oral tablet	25-300 mg/d	QDay	Major depressive disorder	
Desvenlafaxine (Pristiq)	Oral tablet ER	50-100mg/d	QDay	Major depressive disorder	
Doxepin (Silenor)	Oral tablet	3-6 mg/d	QDay	Bipolar disorder, depressive episode; Insomnia, sleep maintenance	
Doxepin	Oral Capsule	10-300 mg/d	QDay to TID	1. Psychoneurotic patients with depression and/or anxiety 2. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol) 3. Depression and/or anxiety associated with organic disease 4. Psychotic depressive disorders with associated anxiety	Max single dose: 150 mg https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/070791s027lbl.pdf
Duloxetine (Cymbalta)	Capsule DR	30-120mg	QDay to BID	Fibromyalgia, Generalized anxiety disorder, Major depressive disorder, Musculoskeletal pain (chronic), Neuropathic pain associated with diabetes mellitus	
Escitalopram (Lexapro)	Oral tablet	5-40 mg/d	QDay		In some pts doses up to 60 mg/d may be necessary for optimal response
Fluoxetine (Prozac)	Oral capsule	10-80 mg/d		Bipolar disorder, Bulimia nervosa, Major depressive disorder, Obsessive-compulsive disorder, Panic disorder	In some pts doses up to 120 mg/d may be necessary for optimal response
Fluoxetine (Prozac Weekly)	Oral capsule Delayed Release	90 mg	Once Weekly	Bipolar disorder, Bulimia nervosa, Major depressive disorder, Obsessive-compulsive disorder, Panic disorder	
Fluoxetine	Oral tablet	5 mg to 80 mg/d	QDay	Bipolar disorder, Bulimia nervosa, Major depressive disorder, Obsessive-compulsive disorder, Panic disorder	In some pts doses up to 120 mg/d may be necessary for optimal response
Fluoxetine (Sarafem)	Oral tablet	10 mg to 30 mg/d	QDay	Premenstrual dysphoric disorder	
Fluvoxamine	Oral capsule Extended Release	100mg-300mg	QDay	Obsessive compulsive disorder	
	Oral tablet	25 mg-300 mg	QDay to BID	Obsessive compulsive disorder	Manufacturer's labeling recommends that daily doses >100 mg be given in 2 divided doses, with the larger dose administered at bedtime
Imipramine pamoate	Oral capsule	75 mg-300mg/d	QDay to TID	Major depressive disorder	
Imipramine hydrochloride	Oral tablet	10mg-300mg/d	QDay to TID	Major depressive disorder	
Imipramine hydrochloride	Oral tablet	25 mg-75mg/d	QDay	Childhood enuresis	Max daily dose (age-dependent): <12 years: 50 mg/day; ≥12 years: 75 mg/day.
Isocarboxazid (Marplan®)	Oral tablet	10 mg to 60 mg/d	BID to QID	Major depressive disorder	Use caution with doses >40 mg/day; experience is limited.
Maprotiline (Ludiomil®)	Oral tablet	25 mg to 225 mg/d	Qday or in divided doses	Major depressive disorder, anxiety associated with depression	
Mirtazapine	Oral tablet & ODT	7.5 mg - 60 mg	QDay	Major depressive disorder	
Nefazodone	Oral tablet	200-600 mg/d	BID	Depression	
Nortriptyline	Oral capsule	25-150 mg/d	QDay to TID	Major depressive disorder	
Paroxetine (Paxil)	Oral tablet	10-100 mg/d	QDay	Generalized anxiety disorder, Major depressive disorder, Obsessive-compulsive disorder, Panic disorder, PTSD, Social anxiety disorder	
Paroxetine (Paxil CR)	Oral tablet, Extended Release	12.5-75 mg/d	QDay	Major depressive disorder, Panic disorder, Premenstrual dysphoric disorder, Social anxiety disorder	
Phenelzine (Nardil®)	Oral tablet	15 mg to 90 mg/d	Qday to TID	Major depressive disorder	
Protriptyline (Vivactil®)	Oral tablet	10 mg to 60 mg/d	TID to QID	Depression	
Selegiline Transdermal (Emsam®)	Transdermal patch	6 mg/24hr to 12 mg/24hr	Qday	Major depressive disorder	
Sertraline (Zoloft)	Oral tablet	25-200 mg/d	QDay	Major depressive disorder, Obsessive-compulsive disorder, Panic disorder, Posttraumatic stress disorder, Premenstrual dysphoric disorder, Social anxiety disorder	
Tranylepromine Sulfate (Pamate®)	Oral tablet	10 mg to 60 mg/d	BID	Major depressive disorder	
Trazodone	Oral tablet	50-400 mg/d	QDay or in divided doses	Major depressive disorder	
Trimipramine (Surmontil®)	Oral capsule	25 mg to 300 mg/d	QHS or in divided doses	Depression	
Venlafaxine HCl (Effexor)	Oral tablet	75 - 225mg/d	BID to TID	Major depressive disorder	
Venlafaxine HCl (Effexor)	Oral tablet, Extended Release	37.5-300 mg/d	QDay	Major depressive disorder, Social anxiety disorder	
Venlafaxine besylate (Effexor)	Oral tablet, Extended Release	112.5 mg to 225 mg/d	QDay	Generalized anxiety disorder, Major depressive disorder	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215429s000lbl.pdf
Venlafaxine HCl (Effexor XR)	Oral capsule, Extended Release	37.5- 300 mg/d	QDay	Generalized anxiety disorder, Major depressive disorder, Panic Disorder, Social anxiety disorder	
Vilazodone	Oral tablet	10-40 mg/d	QDay	Major depressive disorder	
Vortioxetine	Oral tablet	5-20 mg/d	QDay	Major depressive disorder	

Anxiolytic/Hypnotic

Alprazolam	Oral tablet, ODT	0.25-10 mg/d	QDay to QID	Anxiety disorders	
Alprazolam	Oral tablet, Extended Release	0.5-6 mg/d	QDay	Anxiety disorders	
Bupirone	Oral tablet	10 mg to 60 mg/d	BID to TID	Generalized anxiety disorder	
Chlordiazepoxide (Librium)	Oral capsule	5 mg to 300 mg/d	QDay to QID	Anxiety disorders	
Clonazepam	Oral tablet, ODT	0.25 mg to 4 mg/d	QDay to BID pm	Panic disorder	
Clorazepate (Tranxene-T®)	Oral tablet	7.5 mg to 60 mg/d	Qday to QID	Anxiety disorders	Usual dosage: 30 mg/day in divided doses
Daridorexant (Quviviq®)	Oral tablet	25 mt to 50 mg/d	QHS	Insomnia, sleep onset or sleep maintenance	
Diazepam	Oral tablet, oral solution	2 mg to 40 mg/d	QDay to Q3 hours pm	Anxiety disorders; Muscle spasm, spasticity, and/or rigidity	
Eszopiclone (Lunesta)	Oral tablet	1 mg to 3 mg/d	QHS	Insomnia, sleep onset or sleep maintenance	
Flurazepam	Oral capsule	15 mg to 30 mg/d	QHS	Insomnia, sleep onset or sleep maintenance	
Lemborexant (Dayvigo®)	Oral tablet	5 mg to 10 mg/d	QHS	Insomnia, sleep onset or sleep maintenance	
Lorazepam	Oral tablet, oral solution	0.5 mg to 10 mg/d	QDay to Q4 hours pm	Anxiety	Doses upto 30 mg/d have been reported for the treatment of Catatonia (off-label-use)
Oxazepam (Serax®)	Oral capsule	10 mg to 120 mg/d	TID to QID	Anxiety disorders	Usual dosage: 45 to 60 mg/day in divided doses
Ramelteon (Rozerem)	Oral tablet	8 mg/d	QHS	Insomnia, sleep onset	
Suvorexant (Belsomra)	Oral tablet	10 mg to 20 mg/d	QHS	Insomnia, sleep onset or sleep maintenance	
Temazepam (Restoril)	Oral capsule	7.5 mg to 30 mg/d	QHS	Insomnia, sleep onset or sleep maintenance	
Zaleplon (Sonata)	Oral capsule	5-20 mg/d	QHS	Insomnia, sleep onset	
Zolpidem	Oral tablet	5-10mg/d	QHS	Insomnia	
	Oral tablet, Extended Release	6.25-12.5mg/d	QHS	Insomnia	
	Sublingual tablet	1.75-3.5 mg/d	QDay	Insomnia	For Sleep-maintenance insomnia, awakening with 4 hours planned sleep

Mood Stabilizers

Carbamazepine	IR (susp, tab, chewable tab) and ER tabs	100 to 1600 mg a day	IR dosed BID to QID ER dosed BID	Bipolar disorder, Neuropathic pain	Bipolar Disorder: upto 1.8 g/day may be necessary (Stoval, 2019). Significant drug interactions requiring dose adjustment/avoidance
Lamotrigine (Lamictal)	Oral tablet	25 mg to 400 mg/d	every other day, QDay, or in divided doses	Bipolar disorder	Up to 400 mg/d may be necessary in some pts for optimal response, Significant DDIs requiring dose adjustment/avoidance
Lithium	IR (tabs & caps), ER tabs, solution	300 to 1800 mg/day	IR dosed 2 to 3 times daily. ER tabs dosed BID. Solution dosed 2 to 3 times daily	Bipolar disorder	Significant DDIs requiring dose adjustment/avoidance. After 5 to 7 days at a stable therapeutic dose, further adjust as needed based on clinical response, tolerability, and serum concentration. After several weeks at an established dose and stable serum concentrations, may consolidate schedule to a single dose of IR or ER at bedtime.
Valproic Acid (Depakene)	IR (caps/solution, Depakene), Delayed Release Sprinkle (caps, Depakote Sprinkles), DR (tabs, Depakote), ER (tabs, Depakote ER)	500 to 2,500 mg/day. Max 60 mg/kg/day	IR dosed 3 to 4 times daily. DR dosed 2 to 3 times daily. ER dosed 1 to 2 times daily	Bipolar disorder	Available formulations of valproate (active moiety) include valproic acid, valproate sodium, and divalproex sodium (also known as valproate semisodium) salts. All doses are expressed as the equivalent amounts of valproic .Dosing conversions between formulations available on Lexicomp. Significant DDIs requiring dose adjustment/avoidance

ADHD Medications

Clonidine HCl	Oral tablet ER 12 Hour	0.1 mg to 0.4 mg/d	QHS to BID	Attention-deficit/hyperactivity disorder	
Dexmethylphenidate (Focalin)	Oral tablet	2.5 mg to 20 mg/d	BID	Attention-deficit/hyperactivity disorder	Children ≥6 years and Adolescents: Maximum daily dose: 20 mg/day; however, some patients may require and tolerate daily doses up to 50 mg/day with frequent monitoring
Dexmethylphenidate (Focalin XR)	Oral capsule ER	5 mg to 40 mg/d	QDay	Attention-deficit/hyperactivity disorder	Children ≥6 years and Adolescents: Initial: 5 mg once daily; maximum daily dose: 30 mg/day; however, some patients may require and tolerate daily doses up to 50 mg/day with frequent monitoring Adults: initial dose: 10 mg a day; MDD 40 mg/d
Dextroamphetamine/Amphetamine (Adderall)	Oral tablet	• although doses >40 mg/d will rarely be necessary, doses as high as 60 mg/day with close monitoring may be necessary for optimal response in some patients • frequency & severity of AEs are increased with higher doses	QDay to BID	Attention-deficit/hyperactivity disorder; Narcolepsy, daytime sleepiness	
Dextroamphetamine/Amphetamine (Adderall XR)	Oral capsule	• although doses >40 mg/d will rarely be necessary, doses as high as 60 mg/day with close monitoring may be necessary for optimal response in some patients • frequency & severity of AEs are increased with higher doses	QDay	Attention-deficit/hyperactivity disorder	
Dextroamphetamine/Amphetamine (Mydayis)	Triple bead ER caps	12.5 mg to 50 mg	QDay	Attention-deficit/hyperactivity disorder	
Atomoxetine	Oral capsule	40 mg to 100 mg a day	QDay to BID	Attention-deficit/hyperactivity disorder	
Dextroamphetamine	IR tabs, ER caps	5 mg to 60 mg/d	IR dosed BID to TID ER dosed QDay	Attention-deficit/hyperactivity disorder, Narcolepsy	Narcolepsy dosing
Guanfacine (Intuniv®)	Oral ER tablet	0.5 mg to 2 mg /day	QDay	Attention-deficit/hyperactivity disorder	HTN dosing only for adults
Lisdexamfetamine (Vyvanse)	Oral capsule, chewable tabs	30 mg to 70 mg/day	QDay	Attention-deficit/hyperactivity disorder, Binge eating disorder	
Methylphenidate IR (Methylin chewable tabs, solution & Ritalin tabs)	Oral tablet, chewable tabs, & solution	10mg to 60 mg/d	BID to TID	Attention-deficit/hyperactivity disorder, Narcolepsy	Dosing conversions between formulations available on Lexicomp
Methylphenidate Intermediate-acting ER (Metadate ER tabs)	Oral capsule	10 mg to 60 mg/d	BID	Attention-deficit/hyperactivity disorder, Narcolepsy	Dosing conversions between formulations available on Lexicomp. Up to 100 mg/d may be necessary in some pts
Methylphenidate Long-acting ER (Adhansia XR)	Oral capsule, chewable tabs	25 mg to 100 mg/d	QAM	Attention-deficit/hyperactivity disorder	Dosing conversions between formulations available on Lexicomp. Doses >85 mg are associated with higher rate of AEs
Methylphenidate Long-acting ER (Aptensio XR)	Oral capsule	10mg to 60mg	QAM	Attention-deficit/hyperactivity disorder	Dosing conversions between formulations available on Lexicomp
Methylphenidate Long-acting ER (Concerta tabs)	Oral tablet	18 mg to 72 mg	QAM	Attention-deficit/hyperactivity disorder	Dosing conversions between formulations available on Lexicomp
Methylphenidate Long-acting Transdermal (Daytrana patch)	Transdermal topical	10 mg to 30 mg topically	QDay	Attention-deficit/hyperactivity disorder	Up to 60 mg/d may be necessary in some pts
Methylphenidate Long-acting ER (Jornay PM caps)	Oral capsule	20 mg to 100 mg	QPM	Attention-deficit/hyperactivity disorder	
Methylphenidate Long-acting ER (Metadate CD, QuilliChew ER chewable tabs, Quillivant XR susp)	Oral capsule, ER chewable tabs, XR susp	20 mg to 60 mg	QAM	Attention-deficit/hyperactivity disorder	Up to 100 mg/d may be necessary in some pts. QuilliChew ER tabs are scored & may be broken in half for 10 mg and 15 mg doses
Methylphenidate Long-acting ER (Ritalin LA)	Oral capsule	10 mg to 60 mg	QAM	Attention-deficit/hyperactivity disorder	Up to 100 mg/d may be necessary in some pts
Viloxazine (Qelbree)	Oral capsule ER	100 mg to 600 mg/d	Qday	Attention-deficit/hyperactivity disorder	Children 6 to 11 years: Initial: 100 mg once daily; maximum daily dose: 400 mg/day. Children ≥12 years and Adolescents ≤17 years: Initial: 200 mg once daily; maximum daily dose: 400 mg/day Adults: initial dose: 200 mg a day; MDD 600 mg/d.
Amantadine	Oral tablet ER	129 mg to 322 mg/d	QDay	Drug-induced parkinsonism	
Amantadine	Oral tablet IR	200 mg to 300 mg/d	BID to TID	Drug-induced parkinsonism	
Benzotropine	Oral tablet / solution	1 mg to 6 mg/d	QDay to TID	Drug-induced extrapyramidal symptoms, acute treatment	Acute treatment drug-induced extrapyramidal symptoms (excluding tardive dyskinesia).
Diphenhydramine	Oral tablet, capsule, liquid, syrup	25 mg to 200 mg/d	Once to Q4hrs prn	Allergic symptoms, insomnia (occasional), prevention or treatment of motion sickness, antitussive; management of drug-induced extrapyramidal symptoms and parkinsonian syndrome	Allergic symptoms; adjunct to epinephrine in the treatment of anaphylaxis; insomnia (occasional); prevention or treatment of motion sickness; antitussive; management of drug-induced extrapyramidal symptoms (eg, dystonia, parkinsonism) and parkinsonian syndrome alone or in combination with centrally acting anticholinergic agents.
Hydroxyzine	Oral tablet, capsule, syrup	25 mg to 400 mg/d	QDay to QID	Anxiety, Pruritus	Anxiety, Pruritus, Urticaria
Selegiline (Eldepryl®)	Oral capsule, tablet	5 mg to 10 mg/d	BID	Parkinson disease, adjunctive therapy	
Selegiline (Emsam®)	Transdermal Patch	6 mg/24 hr to 12 mg/24 hr	Qday	Major Depressive Disorder	
Trihexyphenidyl	Oral tablet, solution	1 mg to 15 mg/d	TID to QID	Extrapyramidal symptoms, medication-induced; Parkinsonism	

Medication Assisted Treatments

Acamprosate (Campral)	Oral tablet	666 mg to 1998 mg/d	BID to TID	Alcohol use disorder, moderate to severe	666 mg 3 times daily; lower doses (eg, 666 mg 2 times daily) may be considered in patients weighing <60 kg. Some experts consider alternative therapy if goals are not met within 6 months of treatment
Buprenorphine	Oral SL tablet	1 mg to 24 mg/d	Qday	Opioid use disorder	Target dose 16 mg/day. Doses >24 mg/d have not shown to provide any clinical advantage. Buprenorphine 8 mg SL tab = buprenorphine/naloxone 8 mg/2 mg SL film = buprenorphine/naloxone 4.2 mg/0.7 mg buccal film = buprenorphine/naloxone 5.7 mg/1.4 mg SL tab
Buprenorphine/naloxone (Suboxone)	SL Film	Buprenorphine 2 mg/naloxone 0.5 mg to buprenorphine 24 mg/naloxone 6 mg	Qday	Opioid use disorder	
Buprenorphine/naloxone (Suboxone)	SL tablet	Buprenorphine 2 mg/naloxone 0.5 mg to buprenorphine 24 mg/naloxone 6 mg	Qday	Opioid use disorder	Target dose: Buprenorphine (BUP) 16 mg/naloxone 4 mg once daily. Doses higher than buprenorphine 24 mg/naloxone 6 mg have not been demonstrated to provide any clinical advantage
Buprenorphine (Sublocade)	Injection- ER SUBQ	100 mg to 300 mg once monthly	Once monthly (at least 26 days apart)	Opioid use disorder	Treatment of moderate to severe opioid use disorder in pts who have initiated treatment with BUP, followed by dose adjustment for a minimum of 7 days Initial, 300 mg SQ monthly for 2 doses; maintenance 100 mg to 300 mg once monthly, with a minimum of 26 days between doses clinical response For patients in established treatment of 100 mg monthly, a 2-month dosing interval may be appropriate in some instances (eg, extended travel); in those instances, a single 300 mg-dose may be given to cover a 2-month period, then resume 100 mg once monthly
Buprenorphine (Brixadi)	Injection- ER SUBQ	8 mg to 32 mg weekly	Once weekly	Opioid use disorder	Treatment of moderate to severe opioid use disorder (OUD) in patients who have initiated treatment with a single dose of a transmucosal BUP or already being treated with BUP
Buprenorphine (Brixadi)	Injection- ER SUBQ	64 mg to 128 mg monthly	Once monthly	Opioid use disorder	
Chlordiazepoxide (Librium)	Oral capsule	25 mg to 300 mg/d	QDay to Q4Hrs	Alcohol withdrawal syndrome	
Clonidine HCl	Oral tablet	0.1 mg to 1.2 mg/day	QDay to QID	Off label: Opioid withdrawal, medically supervised	
Diazepam (Valium)	Oral tablet, oral solution	5 mg to 40 mg/d	QDay to Q6 rs prn	Alcohol withdrawal syndrome	
Disulfiram	Oral tablet	125 mg to 500 mg	QDay	Alcohol use disorder, moderate to severe	
Gabapentin	Oral tablet, capsule	300 mg to 1,800 mg/d	QDay to TID	Off label: Alcohol use disorder, moderate to severe	Alcohol withdrawal (off-label use)
Nalmefene (Opvee®)	Intranasal spray	2.7 mg/0.1 mL (2 doses per box)	may repeat every 2 to 5 minutes in alternating nostrils for continued or recurrent respiratory depression until medical assistance becomes available	Opioid overdose	
Naloxone Nasal Spray	Intranasal (Narcan®)	4 mg/0.1 ml (2 doses per box)	may repeat every 2 to 3 minutes in alternating nostrils if patient does not respond or responds initially followed by recurrence of respiratory depression until medical assistance becomes available	Opioid overdose	
	Intranasal (Kloxxado®)	8 mg/0.1 mL (2 doses per box)	may repeat every 2 to 3 minutes in alternating nostrils if patient does not respond or responds initially followed by recurrence of respiratory depression until medical assistance becomes available	Opioid overdose	
Naltrexone	Oral tablet	25 mg to 100 mg/d	QDay	Alcohol use disorder, Opioid use disorder	
Naltrexone IM (Vivitrol)	Injection- long acting IM	380 mg once every 4 weeks	Q4weeks	Alcohol use disorder, Prevention of relapse to opioid dependence	
Nicotine Gum	Chewable gum	2 mg to 4 mg (max 24 pieces/d)	1 piece of gum every 1 to 8 hours	Smoking Cessation	Patients who smoke their first cigarette within 30 minutes of waking should use the 4 mg strength; otherwise 2 mg
Nicotine Lozenges	Lozenge	2 mg to 4 mg (max 5 lozenges Q 6 hours)	1 lozenge when urge to smoke occurs	Smoking Cessation	Patients who smoke their first cigarette within 30 minutes of waking should use the 4 mg strength; otherwise 2 mg. Do not use more than 1 lozenge at a time
Nicotine Transdermal	Patch transdermal	7 mg to 21 mg/d	Qday	Smoking Cessation	> 10 cigarettes/d: 21 mg/d transdermally for 6 weeks, then 14 mg/d for 2 weeks, and then 7 mg/d for 2 weeks ≤ 10 cigarettes/d: 14 mg/d for 6 weeks, then 7 mg/d for 2 weeks
Oxazepam	Oral capsule	15 mg to 120 mg/d	QDay to Q6hrs prn	Alcohol withdrawal syndrome	May administer up to 5 additional as-needed 15 to 30 mg doses to be used over the 4-day treatment period for breakthrough symptoms
Topiramate (Topamax)	Oral tablet	25 mg to 300 mg/d	QDay to BID	Off label: Alcohol use disorder, moderate to severe	
Varenicline (Chantix)	Oral tablet	0.5 mg to 2 mg/d	Initial, 0.5 mg QDay for days 1 thru 3, then 0.5 mg BID for days 4 thru 7, then 1 mg BID	Smoking Cessation	Continue maintenance dose for at least 11 weeks (total of at least 12 weeks of treatment). May consider extended maintenance therapy based on individual patient risk:benefit; evidence suggests relapse prevention benefits with continuing therapy for up to 1 year

Weight management

Naltrexone & Bupropion (Contrave)	Oral tablet ER 12 Hour	Naltrexone 8 mg/bupropion 90 mg to naltrexone 32 mg/bupropion 360 mg a day	QDay to BID	Weight management, chronic	
Topiramate (Topamax)	Oral tablet	25 mg to 400 mg/d	QDay to BID	Off label: Binge eating disorder	
Topiramate (Topamax)	Oral tablet	26 mg to 200 mg/d	QDay to BID	Off label: Antipsychotic-induced weight gain	

VMAT₂ Inhibitors

Deutetrabenazine (Austedo®)		11 mg to 48 mg/d	BID	Chorea associated with Huntington's disease, Tardive Dyskinesia in adults	
Deutetrabenazine (Austedo XR®)		12 mg to 48 mg/d	Qday	Chorea associated with Huntington's disease, Tardive Dyskinesia in adults	
Valbenazine (Ingrezza® Ingrezza Sprinkle®)	Oral capsules	40 mg to 80 mg/d	QDay	Chorea associated with Huntington's disease, Tardive Dyskinesia in adults	